

--12. (new) A method of producing a medicinal product intended to induce or simulate the differentiation of cells selected from the group consisting of leukaemic cells and CD14 CD15 strain cells, said method comprising including in said medicinal product a polymer comprising an effective quantity of disaccharide units each composed of an N-acetyl-D-glucosamine structure molecule bonded by an O-glycoside β 1, 4 bond with a glucuronic acid structure molecule.

13. (new) The method according to claim 12 wherein said effective quantity is equivalent to a number of disaccharide units greater than or equal to 3.

14. (new) The method according to claim 12 wherein said effective quantity is equivalent to a number approximately between 3 and 10.

15. (new) The method according to claim 12 wherein said effective quantity is equivalent to a number approximately between 10 and 100.

16. (new) The method according to claim 12 wherein said polymer is composed of hyaluronic acid and the fragments of the same.

17. (new) The method according to claim 12 wherein said polymer is included at a unit dose between approximately 1 and 10 mg/kg inclusive.

18. (new) The method according to claim 17 wherein said unit dose is between approximately 2 and 5 mg/kg.

19. (new) The method according to claim 17 wherein said unit dose is approximately 3 mg/kg.

20. (new) The method according to claim 12 wherein said polymer is present in the form of a solution.

21. (new) The method according to claim 20 wherein said polymer is in an injectable form.

22. (new) The method according to claim 12 wherein said medicinal product further comprises an adjuvant compound capable of stimulating the bonding of said polymer with a cell target.

23. (new) The method according to claim 22 wherein said adjuvant is an anti-CD44 antibody or a fragment thereof.

24. (new) The method according to claim 12 wherein said medicinal product further comprises a compound capable of preventing the bonding of said polymer with an undesired cell target.

25. (new) The method according to claim 24 wherein said compound is an anti-ICAM 1 monoclonal antibody or a fragment thereof.

26. (new) The method of claim 12 wherein said leukaemic cells are at least one of the following: AML1/2, AML3, AML4, AML5, AML6 or AML7 acute myeloblastic leukaemia cells.

27. (new) A medicinal product intended to induce or stimulate the differentiation of CD14⁺ CD15⁻ strain cells and/or leukaemic cells and AML blasts, said product comprising an effective quantity of disaccharide units each comprised of an N-acetyl D-glucosamine structure molecule bonded by an O-glycoside β 1,4 bond with a glucuronic acid structure molecule.--

REMARKS

Reconsideration is requested.